GEN Exclusives

More »

GEN News Highlights

More »
Feb 28, 2011

NovAlix to Perform Drug Discovery Services for Janssen-Cilag

  • NovAlix entered into a multiyear research services agreement to support the drug discovery efforts of Janssen-Cilag. The agreement includes remote and on-site chemistry support by NovAliX scientists. Janssen-Cilag focuses on five therapeutic areas: cardiovascular and metabolic diseases, immunology, infectious diseases and vaccines, neuroscience, and oncology.

     

    NovAlix' technologies include SPR technology, X-ray protein crystallography, and supramolecular mass spectrometry. Its services include organic synthetic chemistry services and biophysical capabilities focused on small molecule drug discovery.

     

    NovAlix expanded its research services capabilities last year through two acquisitions. The company picked up Graffinity Pharmaceuticals for its small molecule library and patented SPR-imaging technology last November. In January 2010, NovAlix bought NMRTec for its NMR solutions capabilities.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?